Lupin receives EIR from US FDA for Goa facility

Lupin receives EIR from US FDA for its Goa facility. The EIR (Establishment Inspection Report) signifies successful completion of FDA inspection at the facility, validating manufacturing practices and quality standards. This regulatory clearance strengthens Lupin's operational credibility in the US market and supports continued product registrations from this site.

📊 STOCKS: LUPIN | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #FDA